BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 8729522)

  • 1. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.
    Robinson S; Henderson AD; Gelding SV; Kiddy D; Niththyananthan R; Bush A; Richmond W; Johnston DG; Franks S
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):277-84. PubMed ID: 8729522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
    Holte J; Bergh T; Berne C; Lithell H
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
    Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.
    Robinson S; Kiddy D; Gelding SV; Willis D; Niththyananthan R; Bush A; Johnston DG; Franks S
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):351-5. PubMed ID: 8222298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic approaches to the subclassification of polycystic ovary syndrome.
    Norman RJ; Masters SC; Hague W; Beng C; Pannall P; Wang JX
    Fertil Steril; 1995 Feb; 63(2):329-35. PubMed ID: 7843439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.
    Conway GS; Agrawal R; Betteridge DJ; Jacobs HS
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):119-25. PubMed ID: 1395062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome.
    Cenk Sayin N; Gücer F; Balkanli-Kaplan P; Ali Yüce M; Yardim T
    Gynecol Endocrinol; 2003 Oct; 17(5):387-96. PubMed ID: 14710586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.
    Pasquali R; Gambineri A; Anconetani B; Vicennati V; Colitta D; Caramelli E; Casimirri F; Morselli-Labate AM
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):517-27. PubMed ID: 10468913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome.
    Grulet H; Hecart AC; Delemer B; Gross A; Sulmont V; Leutenegger M; Caron J
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):621-6. PubMed ID: 8334748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.
    Li L; Feng Q; Ye M; He Y; Yao A; Shi K
    J Obstet Gynaecol; 2017 Nov; 37(8):1036-1047. PubMed ID: 28657375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
    Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
    Ságodi L; Lombay B; Vámosi I; Barkai L
    Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
    Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
    Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
    Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between hormonal and metabolic profiles in women with polycystic ovary syndrome].
    Esposito V; Federico P; Lo Iudice G; Rispoli C; Sabatino P; D'Alessandro B
    Minerva Endocrinol; 1992; 17(1):21-9. PubMed ID: 1495451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?
    Meirow D; Raz I; Yossepowitch O; Brzezinski A; Rosler A; Schenker JG; Berry EM
    Hum Reprod; 1996 Sep; 11(9):1848-53. PubMed ID: 8921052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.